UNLIMITED

STAT

Opinion: What using animals for scientific research taught me about myself

When I looked for the deeper meaning of existence, I found that I was too skeptical for heaven and hell, for deities and spirits. Sometimes, I thought about astrophysics — roiling energy, dark matter, the multiple dimensions of an expanding universe — but it was all too vast and distant. The closest I ever got to a mystical experience was working with animals as a molecular biologist.

As a biologist, I performed experiments on flatworms, sea urchins, zebrafish, frogs, opossums, and mice. These studies required the careful administration of life and death: I merged sperm with eggs and observed early embryos when they were just three layers of tissues flattened together. At certain times, I preserved animals in formaldehyde and bathed them in chemicals that turned their bodies transparent.

In the lab, life and death were demythologized. Instead of some immense, cosmic force, they shrank into something tangible that could be contained in a Petri dish or studied under a microscope.

Read more: Coming to terms with six years in science: obsession, isolation, and moments of wonder

Watching generations of animals flash in and out of existence, I also felt time compressing. I cared for zebrafish embryos that, in a

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min readAmerican Government
Opinion: STAT+: Pharmacy Benefits Managers Should Be Worried
Former FTC policy director David Balto says PBMs should be very worried about the new Trump administration and pending congressional action.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Bill To Force Insurers To Sell Pharmacies, Lilly Testing GLP-1 Meds For Addiction, And More
A bipartisan group of senators are filing a bill that would force health insurers or PBMs to divest their pharmacy businesses
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Novo Holdings Proceeding With Catalent Deal, Sanofi Threatened With Sanctions, And More
Novo Holdings can proceed with its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge the deal

Related Books & Audiobooks